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Review 
Biofluid-based microRNA Biomarkers for Parkinson’s Disease: an 
Overview and Update 
Sapana Shinde, Sayantoni Mukhopadhyay, Ghada Mohsen, and Sok Kean Khoo * 
Department of Cell and Molecular Biology, Grand Valley State University, Grand Rapids,  
MI 49503, USA  
* Correspondence: khoos@gvsu.edu; Tel: +1-616-331-5916. 
Abstract: Parkinson’s disease (PD) is a highly debilitating motor disorder and is the second most 
common neurodegenerative disease after Alzheimer’s disease. Its current method of diagnosis mainly 
relies on subjective clinical rating scales in the presence of clinical motor features. Early detection of 
PD is a known challenge as neuronal cell death may range from 50% to 80% when a patient is first 
diagnosed with PD. Therefore, there is an urgent need to identify and develop biomarkers for early 
detection of this progressive disease. This mini review focuses on the recent developments of 
biofluid-based microRNAs (miRNAs) as molecular biomarkers for PD. A comprehensive list of 
miRNA biomarkers found in blood, plasma, serum, and cerebral spinal fluid is presented. Challenges 
and future perspectives of using these PD-related molecular biomarkers in a “real-world” clinical 
setting are also discussed. 
Keywords: Parkinson’s disease; biomarkers; microRNAs; circulating miRNAs; biofluid; blood; 
serum; plasma; cerebral spinal fluid 
 
1. Introduction 
Parkinson’s disease (PD) is an incurable, progressive movement disorder affecting 
approximately one million Americans (www.pdf.org) and is the 14th leading cause of death in the 
US (www.cdc.gov). The pathogenesis of PD involves the degeneration of neurons, especially 
dopaminergic neurons in the substantia nigra of the midbrain [1], and the presence of Lewy 
bodies/neuritis in various brain regions [2]. Deficiency of the nigro-striatal pathways can cause 
dopamine depletion-specific symptoms such as motor dysfunctions and multiple non-motor clinical 
issues. The clinical diagnosis of PD is based on the four cardinal symptoms: tremor, rigidity, 
bradykinesia, and postural instability [3], which are delayed and subtle. Since the key pathology of 
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PD occurs in the brainstem which is difficult to assess in living patients, it is challenging to monitor 
PD progression in an unbiased and objective manner. Thus, developing reliable clinical diagnostic 
methods that are feasible, objective, measurable, specific and sensitive for PD is essential to improve 
the clinical management of the disease. 
A molecular biomarker is a biological molecule found in blood, other bodily fluids or tissues 
that can be measured as an indicator of a normal or abnormal biological process, or of a disease 
condition. Molecular biomarkers can be used as a diagnostic or prognostic tool for a specific disease. 
In PD, biochemical biomarkers which are heavily based on alpha-synuclein (SNCA), the primary 
structural component of Lewy bodies, have been proposed in the past few years [4]. This mini review 
will focus on the most recent development of non-SNCA, microRNA (miRNA)-based biomarkers 
identified in various biofluids for PD diagnosis. 
2. miRNAs as informative biomarkers for specific diseases 
miRNAs are a family of short (18–22 nucleotides), single-stranded non-coding RNAs that act as 
gene expression modulators at the post-transcriptional level to fine-tune the expression of specific 
messenger RNAs (mRNAs) [5,6]. Many miRNAs can target multiple mRNAs by recognizing short, 
specific complementary sequences in the mRNAs and control the expression of hundreds to 
thousands of genes [7,8]. miRNA expression profiling has been used frequently to identify 
biomarkers and/or molecular pathways associated with specific human diseases. miRNAs are also 
known to be highly abundant, tissue-specific, quantifiable, highly stable with non-post process 
modification, which are “ideal” characteristics of biomarkers. In neurodegeneration, although the 
pathogenic mechanisms are complex and not fully defined, deregulation of miRNAs has been 
increasingly recognized to play important roles in the process [9]. There is also emerging evidence 
describing the important roles of miRNAs in neuronal processes such as neuronal differentiation and 
neuroplasticity. miRNAs as potential clinical biomarkers for PD has been described extensively in 
our previous review [10].  
3. Biofluids are excellent biomarker resources 
Biological fluids or biofluids are liquids originating from human bodies. They are an excellent 
source for biomarker research as their close proximity to cells can potentially reflect their 
biochemical contents and hence the biological conditions of the cells [11]. Common biofluids used in 
biomarker research include peripheral blood, blood serum or plasma, saliva, urine, and cerebral 
spinal fluid (CSF). Deregulation of blood miRNAs has been significantly correlated with 
disease-associated genetic variants [12]. Since biofluid sample collection is inexpensive, rapid, 
simple, and minimally invasive (except for CSF), it has a large advantage over other solid or 
semi-solid biospecimens for studying disease biomarkers. 
4. miRNAs detection in peripheral blood of PD patients 
Blood is an ideal source for biomarkers because it can be obtained in a simple, fast, low-cost and 
minimally invasive manner. The first report of peripheral blood-based miRNA biomarkers for PD was 
demonstrated in 2011 by a quantitative real-time PCR (qRT-PCR) approach [13]. A set of 3 miRNAs 
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(miR-1, miR-22*, and miR-29a) with lower miRNA expression was identified when compared 
between de novo and treated PD vs. control and early-onset PD. A second set of 3 miRNAs 
(miR-16-2*, miR-26a2*, and miR-30a) showed 50% higher expression in treated PD vs. control 
subjects (Table 1). The second report applied a microarray approach to identify 18 under-expressed 
miRNAs in peripheral blood mononuclear cells of PD vs. control [14]. The third report used a 
combination of small RNA next-generation sequencing (small RNA-seq) and exon microarray 
technologies to investigate miRNA expression in blood leukocytes (white blood cells) of healthy 
controls as well as PD patients before and after deep brain stimulation (DBS) treatment [15]. A set of 5 
miRNAs (miR-4293, miR-378c, miR-18b*, miR-20a, and miR-1249) that are under-expressed in PD 
vs. DBS has inversed/higher expression in controls when compared with PD, suggesting both 
treatment and disease related changes in miRNA expression. Interestingly, down-regulation of 
miR-29a, miR-29c, miR-30c, and miR-19b can also be observed in white blood cells of PD DBS-off vs. 
DBs-on patients and/or in the serum of PD vs. control (see Table 1 and cmiRNAs in plasma/serum 
section below). Unfortunately, detection sensitivity of miRNA expression among biofluid types (i.e., 
peripheral blood vs. mononuclear cells vs. white blood cells vs. serum) could not be evaluated mainly 
due to different technologies (i.e., qRT-PCT, microarray and next-generation sequencing) used among 
these studies. 
5. The potential of circulating miRNAs (cmiRNAs) as disease-related biomarkers  
The presence of circulating miRNAs (cmiRNAs) was first described in the serum of diffuse 
large B-cell lymphoma patients [16]. Since then, many studies have shown that miRNAs exist not 
only at the cellular level but also as circulating, cell-free miRNAs in serum, plasma, and CSF. There 
are several hypotheses of how cmiRNAs can be released into circulatory systems: 1) direct leakage 
of cellular miRNAs as by-products of tissue damage or apoptosis due to certain pathological 
conditions (such as metastasis or inflammation), 2) active secretion by cells as free miRNAs with or 
without cell stimulation, and 3) secretion in the form of cell-derived microvesicles (eg. 
microparticles and exosomes), apoptotic bodies, miRNA-protected proteins (eg. Ago2 and NPM1) or 
high-density lipoprotein [17–22]. 
Similar to miRNAs, cmiRNAs are highly stable and resistant to RNase activity, extreme pH and 
temperature [23,24]. cmiRNA expression are also known to correlate with various human diseases, 
especially cancers [17]. In PD, we performed a proof-of-concept study and first reported a panel of 
four cmiRNA as potential PD biomarkers [25]. With high stability and capacity to reflect disease 
status, cmiRNAs have great potential as molecular biomarkers for diagnosis and prognosis of 
neurodegenerative diseases. Readers can further refer to a review by Sheinerman and Umansky [26] 
on cmiRNAs biomarkers for various neurodegenerative diseases and three common approaches used 
for such studies. In Alzheimer’s disease (AD), miRNA expression changes in brain and CSF have 
provided insights into the disease pathways [27]. Therefore, besides their utility as disease 
biomarkers, cmiRNA may provide new insights for the pathogenesis of PD. 
6. Identification of cmiRNA biomarkers in blood plasma/serum for PD 
We published the first report of four plasma-based cmiRNAs (miR-1826, miR-450b-3p, 
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miR-626, and miR-505) as a panel of potential biomarkers for PD using Agilent microarrays 
followed by a qRT-PCR approach [25]. A validation study using a new, independent cohort has been 
carried out to confirm the reproducibility and robustness of these candidate biomarkers. One year 
later, another group used the TaqMan low-density microarray cards and qRT-PCR and found 
miR-331-5 significantly up-regulated in plasma of PD patients compared with healthy controls [28]. 
Both findings are mutually exclusive and could be explained by used of 1) different discovery 
platforms which may have different detection sensitivities, 2) different statistical algorithms to 
identify differentially-expressed cmiRNAs, and 3) treated PD patients in the formal and naïve PD 
patients in the later report. 
Recently, three additional studies on serum-based cmiRNA biomarkers for PD have been 
reported. Four differentially-expressed cmiRNAs (miR-399-5p, miR-223*, miR-324-3p, and miR-24) 
were identified and validated in PD and MSA (multiple system atrophy) vs. control subjects [29]. 
The same cmiRNAs (except miR-339-5p) were identified in PD vs. control, in addition to miR-30c 
and miR-148b which were down-regulated. Interestingly, miR-30c was also found down-regulated in 
the peripheral blood mononuclear cell of PD when compared with control. Another report used PD 
and LRRK2 (leucine-rich repeat kinase 2) PD as discovery and first validation cohort to identify 4 
statistically significant cmiRNAs (miR-29a, miR-29c, miR-19a, and miR-19b) in PD vs. control in a 
second validation study [30]. Strikingly, down-regulation of miR-29a, miR-29c, miR-30c, and 
miR-19b were also shown in previous blood-based biomarker studies [13,14]. Repeated detection of 
similar miRNAs regardless of biofluid types and detection technologies make these miRNAs strong 
biofluid-based biomarker candidates for PD which need to be validated. In another miRNA 
expression profiling study using small next-generation sequencing on post mortem sera, 5 
differentially-expressed cmiRNAs were identified between PD and control [31]. 
7. cmiRNA expression is altered in PD’s CSF 
Small RNA-seq was also recently used to detect 17 differentially-expressed cmiRNAs in post 
mortem CSF of PD or AD patients vs. healthy controls [31]. Although one differentially-expressed 
cmiRNA was identified in both CSF and serum for AD, there was no overlapping cmiRNA candidate 
in CSF and serum from the same PD patients. This finding suggests that cmiRNA expression in 
serum may not be corresponding to those in CSF which is directly connected to the central nervous 
system; CSF and serum may not provide similar cmiRNA expression profiles in this case. Moreover, 
the viability of cmiRNA expression in postmortem vs. fresh serum and CSF is relatively unknown 
and worth investigation.  
Table 1 summarizes the biofluid-based miRNA studies for PD mentioned above. 
8. Current limitations of biofluid-based miRNA biomarkers  
Biofluid-based miRNA biomarker research for PD has been emerging rapidly. cmiRNAs are 
envisioned to become potential biomarkers for early detection and progression of PD. However, 
there are several impeding factors that may come into play. First, miRNAs usually exist in much 
lower amounts in biofluids than tissues. Hence, depending on the sensitivity of the detection 
techniques, they can remain undetected and be missed as potential biomarkers. Fortunately, recent 
advancements of non-biased amplification and enrichment techniques have substantially improved
19 
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Table 1. Biofluid-based miRNA expression studies in Parkinson’s disease. 
miRNA Biofluid type Sample size Sample type Method Reference 
↓ miR-29a Peripheral 
blood 
 
White blood 
cells 
 
Serum 
 
 
15 PD vs. 8 CTR 
 
 
7 PD vs. 6 CTR 
 
 
Discovery set: 
10 PD, 10 LRRK2 PD vs. 10 CTR 
Validation set 1: 
20 PD, 20 LRRK2 PD vs. 20 CTR 
Validation set 2: 65 PD vs. 65 CTR 
de novo PD + 
levodopa/carbidopa treated vs. 
CTR + early onset PD 
 
PD (DBS-off) vs. PD (DBS-on)
 
 
PD vs. CTR 
 
 
 
qRT-PCR 
(SYBR green) 
 
Small RNA-sequencing  
(ABI SOLiD) 
 
TaqMan Low  
Density miRNA array v.2.0 A, 
validation by qRT-PCR 
(TaqMan) 
Margis et al., 2011 
 
 
Soreq et al., 2013 
 
 
Botta-Orfila et al., 2014 
↓ miR-29c Peripheral 
blood 
mononuclear 
cell 
 
 
White blood 
cell 
 
Serum 
 
 
 
19 PD vs.13 CTR 
 
 
 
 
 
7 PD vs. 6 CTR 
 
 
Discovery set: 
10 PD, 10 LRRK2 PD vs. 10 CTR 
Validation set 1: 
20 PD, 20 LRRK2 PD vs. 20 CTR 
Validation set 2: 65 PD vs. 65 CTR 
PD vs. CTR 
 
 
 
 
 
PD (DBS-off) vs. PD (DBS-on)
 
 
PD vs. CTR 
 
Exiqon  
miRCURY LNA array v.10.0, 
validation by qRT-PCR 
(TaqMan) 
 
Small RNA-sequencing  
(ABI SOLiD) 
 
TaqMan Low  
Density miRNA array v.2.0 A, 
validation by qRT-PCR 
(TaqMan) 
Martins et al., 2011 
 
 
 
 
 
Soreq et al., 2013 
 
 
Botta-Orfila et al., 2014 
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↓ miR-30c Peripheral 
blood 
mononuclear 
cell  
 
 
Serum 
19 PD vs.13 CTR 
 
 
 
 
 
Discovery set: 
6 PD, 6 MSA-P, 3 MSA-C vs.  5 
CTR 
Validation set: 25 PD, 25 MSA, vs. 
25 CTR 
PD vs. CTR 
 
 
 
 
 
PD vs. CTR 
 
Exiqon  
miRCURY LNA array v.10.0, 
validation by qRT-PCR 
(TaqMan) 
 
TaqMan Low  
Density miRNA array v.3.0 A 
and B,  
validation by qRT-PCR 
(TaqMan) 
Martins et al., 2011 
 
 
 
 
 
Vallelunga et al., 2014 
↓ miR-19b Peripheral 
blood 
mononuclear 
cell  
 
 
Serum 
 
19 PD vs.13 CTR 
 
 
 
 
 
Discovery set: 
10 PD, 10 LRRK2 PD vs. 10 CTR 
Validation set 1: 
20 PD, 20 LRRK2 PD vs. 20 CTR 
Validation set 2: 65 PD vs. 65 CTR 
PD vs. CTR 
 
 
 
 
 
PD vs. CTR 
 
 
Exiqon  
miRCURY LNA array v.10.0, 
validation by qRT-PCR 
(TaqMan) 
 
TaqMan Low  
Density miRNA array v.2.0 A, 
validation by qRT-PCR 
(TaqMan) 
Martins et al., 2011 
 
 
 
 
 
Botta-Orfila et al., 2014 
↓ miR-1, miR-22* 
 
 
↑ miR-16-2*, miR-26a2*, 
miR-30a 
Peripheral 
blood 
15 PD vs. 8 CTR de novo PD + 
levodopa/carbidopa treated vs. 
CTR + early onset PD  
 
levodopa/carbidopa treated vs. 
CTR 
qRT-PCR 
(SYBR green) 
Margis et al., 2011 
↓ miR-335, miR-374a, 
miR-199a-3p/miR-199b-3p, 
Peripheral 
blood 
19 PD vs.13 CTR PD vs. CTR 
 
Exiqon  
miRCURY LNA array v.10.0, 
Martins et al., 2011 
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miR-126*, miR-151-3p, 
miR-199a-5p, miR-151-5p, 
miR-126, miR-29b, miR-147, 
miR-28-5p, miR-30b, miR-374b, 
miR-301a, miR-26a 
mononuclear 
cell  
validation by qRT-PCR 
(TaqMan) 
↓ miR-320a/b/c, miR-769, 
miR-92b, miR-16 
↑ miR-199b, miR-1274b, 
miR-21, miR-150, miR-671, 
miR-1249, miR-20a, miR-18b*, 
miR-378c, miR-4293 
 
↓ miR-4293, miR-378c, 
miR-18b*, miR-424*, miR-20a, 
miR-210, miR-1249, miR-93 
↑ miR-4317, miR-143, miR-424 
 
↓ miR-652, miR-15a*, 
miR-376c, miR-143 
↑ miR-423, miR-365, miR-486, 
miR-1260, miR-218 
White blood 
cell  
7 PD vs. 6 CTR PD (pre-DBS) vs.  CTR 
 
 
 
 
 
 
 
PD (pre-DBS) vs. PD 
(post-DBS) 
 
 
 
 
 
 
PD (DBS-off) vs PD (DBS-on) 
Small RNA-sequencing  
(ABI SOLiD) 
Soreq et al., 2013 
A panel of four miRNA 
biomarkers 
↑ miR-1826,  
↓ miR-450b-3p 
↑ miR-626, miR-505 
Plasma Discovery set: 32 PD vs.32 CTR 
Replication set: 42 PD vs.30 CTR 
Validation set: 30 PD, 4 MSA, 5 PSP 
vs. 8 CTR 
PD (treated) vs. CTR 
 
Agilent miRNA microarray 
v.3, 
validation by qRT-PCR 
(TaqMan) 
Khoo et al., 2012 
↑ miR-331-5p Plasma 31 PD vs. 25 CTR PD (non-treated) vs. CTR 
 
TaqMan Low Density miRNA 
array (3 pools of PD and 
CTR), 
Cardo et al., 2013 
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then qRT-PCR (TaqMan)  
↓ miR-339-5p 
↑ miR-223*, miR-324-3p, 
miR-24 
 
↓ miR-148b  
↑ miR-223*, miR-324-3p, 
miR-24 
Serum Discovery set: 
6 PD, 6 MSA-P, 3 MSA-C vs. 5 CTR
Validation set: 25 PD, 25 MSA, vs. 
25 CTR 
PD + MSA vs. CTR 
 
 
 
PD vs. CTR 
TaqMan Low  
Density miRNA array v.3.0 A 
and B,  
validation by qRT-PCR 
(TaqMan) 
Vallelunga et al., 2014 
↓ miR-19a  Serum Discovery set: 
10 PD, 10 LRRK2 PD vs. 10 CTR 
Validation set 1: 
20 PD, 20 LRRK2 PD vs. 20 CTR 
Validation set 2: 65 PD vs. 65 CTR 
PD vs. CTR 
 
 
 
 
 
 
TaqMan Low  
Density miRNA array v.2.0 A, 
validation by qRT-PCR 
(TaqMan) 
Botta-Orfila et al., 2014 
↓ miR-16-2-3p, miR-1294 
↑ miR-338-3p, miR-30e-3p, 
miR-30a-3p 
 
↓ miR-132-5p, miR-485-5p, 
miR-127-3p, miR-128, 
miR-409-3p, miR-433, miR-370, 
miR-431-3p, miR-873-3p, 
miR-136-3p, miR-212-3p, 
miR-10a-5p, miR-1224-5p, 
miR-4448 
↑ miR-19a-3p, miR-19b-3p, 
let-7g-3p 
Serum 
(post mortem)
 
 
CSF 
(post mortem)
50 PD vs. 62 CTR 
 
 
 
 
57 PD vs. 65 CTR 
PD vs.  CTR 
 
 
 
 
PD vs. CTR 
 
Small RNA Sequencing 
(Illumina HiSeq2000) 
Burgos et al., 2014 
PD: Parkinson’s disease; CTR: healthy control; PSP: progressive supranuclear palsy; MSA: multiple system atrophy; LRRK2 PD: G2019S mutation in PD;  
DBS: Deep brain stimulation; ↓: down-regulated miRNA expression; ↑: up-regulated miRNA expression. 
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the detection sensitivity of miRNA expression. Second, biomarker research is known for its 
complexity and difficulty in correlating different biomarker data from different reports. As shown in 
Table 1, biomarkers in bodily fluids are screened and analyzed by a variety of techniques. Variations 
may also involve sample collection and storage, sample preparation, data normalization and data 
analysis [10]. Therefore, a unifying method and/or technique should be applied for each specific 
biomarker in general. However, in a “real-world” clinical setting, standardization from the beginning 
of sample collection to assay processes may not be feasible or realistic. This also brings us to the 
third limitation where either small or no validation studies were performed to confirm the 
reproducibility and robustness of these biofluid-based biomarker candidates and its assays; this 
drawback has further delayed the incorporation of molecular biomarkers into routine preclinical or 
clinical applications. Fourth, the presence of miRNAs in biological fluids as a disease indicator 
remains a subject of considerable debate. Although deregulation of miRNAs has been increasingly 
recognized to play important roles in neurodegeneration [9], the potential of utilizing miRNAs to 
reflect pathogenic changes in the brain needs to be further investigated and validated. 
9. Future perspectives   
This mini review shows that miRNAs in bodily fluids hold promise as potential molecular 
biomarkers for PD. Unique characteristics of miRNAs and cmiRNAs make them highly attractive as 
molecular biomarkers. Follow-up validation studies and standardization are critical to ensure 
successful development of sensitive and specific biomarkers for PD. The finding of stable cmiRNAs 
in biofluids suggests their possible function as mediators in cell-cell communication in response to 
biological stimuli [32]. Thus, it is possible that cmiRNAs in serum or plasma may directly or 
indirectly reflect the pathological status of the brain. It is also known that miRNAs can be 
transported by exosomes which are lipid microvesicles of endocytic origin secreted by many cell 
types, including neurons, astrocytes, oligodendrocytes, and microglia [33–36]. Recent evidence has 
shown the involvement of exosomes in the pathogenesis of PD [37]. Although the association of 
exosome-based miRNAs in neurodegeneration has not been established, it is worth future 
investigation. 
In AD, cmiRNAs in CSF and serum have been identified to correlate with the severity of 
disease such as Braak stages, neurofibrillary tangle and plaque-density scores [27,31]. Hence, future 
investigation of cmiRNA expression in correlation with PD severity (e.g. SNCA accumulation or 
Lewy bodies) may accelerate discovery of progression biomarkers for PD. In summary, establishing 
and validating biofluid-based miRNA biomarkers may facilitate the development of objective 
diagnostic and prognostic molecular tools for PD to translate basic research discovery to clinical 
setting. 
Acknowledgements  
S.K. Khoo is supported by grants from the Michael J. Fox Foundation for Parkinson’s Research.  
Conflict of interest  
All authors declare no conflict of interest. 
24 
AIMS Medical Science  Volume 2, Issue 1, 16-26. 
References 
1. Braak H, Del Tredici K, Rub U, et al. (2003) Staging of brain pathology related to sporadic 
Parkinson's disease. Neurobiol Aging 24: 197-211.  
2. Savitt JM, Dawson VL, Dawson TM (2006) Diagnosis and treatment of Parkinson disease: 
molecules to medicine. J Clin Invest 116: 1744-1754.  
3. Dickson DW, Braak H, Duda JE, et al. (2009) Neuropathological assessment of Parkinson's 
disease: refining the diagnostic criteria. Lancet Neurol 8: 1150-1157.  
4. Schapira AH (2013) Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol 
26: 395-400.  
5. Liotta LA, Ferrari M, Petricoin E (2003) Clinical proteomics: written in blood. Nature 425: 905.  
6. Keller A, Leidinger P, Bauer A, et al. (2011) Toward the blood-borne miRNome of human 
diseases. Nat Methods 8: 841-843.  
7. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350-355.  
8. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 
281-297.  
9. Lim LP, Lau NC, Garrett-Engele P, et al. (2005) Microarray analysis shows that some 
microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773.  
10. Hobert O (2008) Gene regulation by transcription factors and microRNAs. Science 319: 
1785-1786.  
11. Goodall EF, Heath PR, Bandmann O, et al. (2013) Neuronal dark matter: the emerging role of 
microRNAs in neurodegeneration. Front Cell Neurosci 7: 178.  
12. Khoo SK, Neuman LA, Forsgren L, et al. (2013) Could miRNA expression changes be a reliable 
clinical biomarker for Parkinson's disease? Neurodegener Dis Manag 3: 455-465.  
13. Lawrie CH, Gal S, Dunlop HM, et al. (2008) Detection of elevated levels of tumour-associated 
microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 
672-675.  
14. Zen K, Zhang CY (2012) Circulating microRNAs: a novel class of biomarkers to diagnose and 
monitor human cancers. Med Res Rev 32: 326-348.  
15. Valadi H, Ekstrom K, Bossios A, et al. (2007) Exosome-mediated transfer of mRNAs and 
microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659.  
16. Hunter MP, Ismail N, Zhang X, et al. (2008) Detection of microRNA expression in human 
peripheral blood microvesicles. PloS One 3: e3694.  
17. Zernecke A, Bidzhekov K, Noels H, et al. (2009) Delivery of microRNA-126 by apoptotic bodies 
induces CXCL12-dependent vascular protection. Sci Signal 2: ra81.  
18. Wang K, Zhang S, Weber J, et al. (2010) Export of microRNAs and microRNA-protective 
protein by mammalian cells. Nucleic Acids Res 38: 7248-7259.  
19. Vickers KC, Palmisano BT, Shoucri BM, et al. (2011) MicroRNAs are transported in plasma and 
delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13: 423-433.  
20. Mitchell PS, Parkin RK, Kroh EM, et al. (2008) Circulating microRNAs as stable blood-based 
markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513-10518. 
21. Chen X, Ba Y, Ma L, et al. (2008) Characterization of microRNAs in serum: a novel class of 
biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006.  
22. Khoo SK, Petillo D, Kang UJ, et al. (2012) Plasma-based circulating microRNA biomarkers for 
25 
AIMS Medical Science  Volume 2, Issue 1, 16-26. 
Parkinson's disease. J Parkinson Dis 2: 321-331.  
23. Sheinerman KS, Umansky SR (2013) Circulating cell-free microRNA as biomarkers for 
screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic 
pathologies. Front Cell Neurosci 7: 150.  
24. Cogswell JP, Ward J, Taylor IA, et al. (2008) Identification of miRNA changes in Alzheimer's 
disease brain and CSF yields putative biomarkers and insights into disease pathways. J 
Alzheimers Dis 14: 27-41.  
25. Margis R, Rieder CR (2011) Identification of blood microRNAs associated to Parkinsonis 
disease. J Biotechnol 152: 96-101.  
26. Martins M, Rosa A, Guedes LC, et al. (2011) Convergence of miRNA expression profiling, 
alpha-synuclein interacton and GWAS in Parkinson's disease. PloS one 6: e25443.  
27. Soreq L, Salomonis N, Bronstein M, et al. (2013) Small RNA sequencing-microarray analyses in 
Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain 
region transcriptomes. Front Mol Neurosci 6: 10.  
28. Cardo LF, Coto E, de Mena L, et al. (2013) Profile of microRNAs in the plasma of Parkinson's 
disease patients and healthy controls. J Neurol 260: 1420-1422.  
29. Burgos K, Malenica I, Metpally R, et al. (2014) Profiles of extracellular miRNA in cerebrospinal 
fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease 
status and features of pathology. PLoS One 9: e94839.  
30. Botta-Orfila T, Morato X, Compta Y, et al. (2014) Identification of blood serum micro-RNAs 
associated with idiopathic and LRRK2 Parkinson's disease. J Neurosci Res 92: 1071-1077.  
31. Wang K, Zhang S, Weber J, et al. (2010) Export of microRNAs and microRNA-protective 
protein by mammalian cells. Nucleic acids res 38: 7248-7259.  
32. Faure J, Lachenal G, Court M, et al. (2006) Exosomes are released by cultured cortical neurones. 
Mol Cell Neurosci 31: 642-648.  
33. Potolicchio I, Carven GJ, Xu X, et al. (2005) Proteomic analysis of microglia-derived exosomes: 
metabolic role of the aminopeptidase CD13 in neuropeptide catabolism. J Immunol 175: 
2237-2243.  
34. Kramer-Albers EM, Bretz N, Tenzer S, et al. (2007) Oligodendrocytes secrete exosomes 
containing major myelin and stress-protective proteins: Trophic support for axons? Proteom Clin 
appl 1: 1446-1461.  
35. Lachenal G, Pernet-Gallay K, Chivet M, et al. (2011) Release of exosomes from differentiated 
neurons and its regulation by synaptic glutamatergic activity. Mol Cell Neurosci 46: 409-418.  
36. Russo I, Bubacco L, Greggio E (2012) Exosomes-associated neurodegeneration and progression 
of Parkinson's disease. Am J Neurodegener Dis 1: 217-225. 
© 2015, Sok Kean Khoo, et al., licensee AIMS Press. This is an open access article distributed 
under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0) 
 
